vs
Side-by-side financial comparison of Viking Holdings Ltd (VIK) and Zoetis (ZTS). Click either name above to swap in a different company.
Viking Holdings Ltd is the larger business by last-quarter revenue ($4.0B vs $2.3B, roughly 1.8× Zoetis). Zoetis runs the higher net margin — 26.6% vs 12.9%, a 13.7% gap on every dollar of revenue.
Norwegian Cruise Line Holdings (NCLH) is a holding company that is based in the United States and domiciled in Bermuda. It operates three cruise lines as wholly owned subsidiaries: Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. With its subsidiaries combined, it is the third-largest cruise operator in the world. It is a publicly traded company listed on the New York Stock Exchange.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
VIK vs ZTS — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.0B | $2.3B |
| Net Profit | $514.0M | $601.0M |
| Gross Margin | 73.4% | 71.7% |
| Operating Margin | 15.2% | — |
| Net Margin | 12.9% | 26.6% |
| Revenue YoY | — | 2.9% |
| Net Profit YoY | 35.4% | -0.2% |
| EPS (diluted) | $1.15 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.3B | ||
| Q4 25 | — | $2.4B | ||
| Q3 25 | $4.0B | $2.4B | ||
| Q2 25 | $2.3B | $2.5B | ||
| Q1 25 | $718.2M | $2.2B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $3.6B | $2.4B | ||
| Q2 24 | $2.1B | $2.4B |
| Q1 26 | — | $601.0M | ||
| Q4 25 | — | $603.0M | ||
| Q3 25 | $514.0M | $721.0M | ||
| Q2 25 | $439.2M | $718.0M | ||
| Q1 25 | $-105.5M | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | $379.7M | $682.0M | ||
| Q2 24 | $159.8M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | 73.4% | 71.5% | ||
| Q2 25 | 55.7% | 73.6% | ||
| Q1 25 | 17.3% | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | 74.7% | 70.6% | ||
| Q2 24 | 57.8% | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 31.9% | ||
| Q3 25 | 15.2% | 37.0% | ||
| Q2 25 | 23.7% | 36.7% | ||
| Q1 25 | -1.3% | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | 13.6% | 36.6% | ||
| Q2 24 | 20.5% | 33.0% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | — | 25.3% | ||
| Q3 25 | 12.9% | 30.0% | ||
| Q2 25 | 19.1% | 29.2% | ||
| Q1 25 | -14.7% | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | 10.6% | 28.6% | ||
| Q2 24 | 7.7% | 26.4% |
| Q1 26 | — | $1.42 | ||
| Q4 25 | — | $1.37 | ||
| Q3 25 | $1.15 | $1.63 | ||
| Q2 25 | $0.99 | $1.61 | ||
| Q1 25 | $-0.24 | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | $0.87 | $1.50 | ||
| Q2 24 | $0.38 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $803.5M | — |
| Total Assets | $11.5B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $3.0B | $2.1B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.8B | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $2.4B | $1.7B | ||
| Q2 24 | $1.8B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | $803.5M | $5.4B | ||
| Q2 25 | $278.3M | $5.0B | ||
| Q1 25 | $-267.5M | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | $-688.9M | $5.2B | ||
| Q2 24 | $-1.1B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | $15.5B | ||
| Q3 25 | $11.5B | $15.2B | ||
| Q2 25 | $11.1B | $14.5B | ||
| Q1 25 | $10.7B | $14.1B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | — | $14.4B | ||
| Q2 24 | — | $14.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $663.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $893.0M | ||
| Q3 25 | $663.9M | $938.0M | ||
| Q2 25 | $470.7M | $486.0M | ||
| Q1 25 | $587.9M | $587.0M | ||
| Q4 24 | — | $905.0M | ||
| Q3 24 | $828.7M | $951.0M | ||
| Q2 24 | $419.8M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.48× | ||
| Q3 25 | 1.29× | 1.30× | ||
| Q2 25 | 1.07× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 2.18× | 1.39× | ||
| Q2 24 | 2.63× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VIK
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
